Arexvy is a vaccine used to protect adults 18 years of age and older against lower respiratory tract disease (LRTD, diseases of the lungs such as bronchitis or pneumonia) caused by respiratory syncytial virus (RSV). Arexvy contains a version of a protein found on the surface of the virus called RSVPreF3.
Therapeutic Indication
### Therapeutic indication Arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 18 years of age and older. The use of this vaccine should be in accordance with official recommendations.
Therapeutic Area (MeSH)
ATC Code
J07BX05
ATC Item
respiratory syncytial virus vaccines
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Respiratory Syncytial Virus recombinant glycoprotein F stabilised in the pre-fusion conformation (RSVPreF3) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology | N/A | respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref 3) produced in chinese hamster ovary (cho) cells by recombinant dna technology |
EMA Name
Arexvy
Medicine Name
Arexvy
Aliases
N/ANo risk management plan link.
